ISIN:FR0012333284

EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Retrieved on: 
Mercredi, avril 10, 2024
EST, Q&A, Patient, Webcast, Document, Annual report, Euronext Paris, AMF, Therapy, Cryptocurrency

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Key Points: 
  • Abivax publishes financial reports with the French and U.S. securities regulatory agencies
    The issuer is solely responsible for the content of this announcement.
  • The Universal Registration Document includes the 2023 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.
  • To participate and ask questions during the webcast, please register via the Abivax website .

EQS-News: Abivax reports 2023 financial results and operational update

Retrieved on: 
Mercredi, avril 10, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

EQS-News: Abivax meldet Finanzergebnisse für das Geschäftsjahr 2023 und gibt Update zur Unternehmensentwicklung

Retrieved on: 
Mercredi, avril 10, 2024
Aufwand, Forschung, Entwicklung, F&E, Vergleich, Anstieg, Investition, Aufwendung, Zusammenhang, Programm, Behandlung, MC, Verwaltungskosten, Abschreibung, Krebs, Personalkosten, Ausgabe, Mitarbeiter, Punkt, Zinsaufwand, Anleihe, Kredit, Zeitwert, Zug, Kursfeststellung, NASDAQ, Tranche, Unternehmen, Capital, Claret, The European, Fremdfinanzierung, Anspruch, Schadensersatz, Finanzierungsbedarf, Quartal, Kolitis

EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)

Retrieved on: 
Mardi, février 13, 2024
Therapy, Ulcerative colitis, European, A12, UC, Abstract, Patient, IBD, Symposium, Congress, Symposium (Plato), Ulcer, Euronext Paris, ECCO, Pharmaceutical industry

“We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.

Key Points: 
  • “We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.
  • We look forward to scientific exchange with the IBD community at ECCO,” said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax.
  • (Germany), on February 23, 2024, at 7:15-8:15 a.m. CET in room A12.
  • The Symposium will be broadcasted live and is accessible publicly here .